tldrdailynews.com logo

"Gilead's Stock Plummets as Lung Cancer Treatment Trial Disappoints"

1 min read
Source: MarketWatch
"Gilead's Stock Plummets as Lung Cancer Treatment Trial Disappoints"
Photo: MarketWatch
TL;DR

Gilead Sciences' stock plunges over 10% in premarket trading after disappointing trial results for its lung cancer treatment, Trodelvy, failing to meet its primary endpoint of overall survival in previously treated metastatic non-small cell lung cancer. The company plans to discuss the results with regulators, expressing continued confidence in Trodelvy's potential in metastatic NSCLC despite the setback.

Topics:businessfinance#clinical-trial#finance#gilead-sciences#lung-cancer-treatment#selloff#stock-market
Share this article
  1. Gilead’s stock tumbles toward biggest selloff in more than 9 years after lung cancer treatment trial disappoints  MarketWatch
  2. Gilead's Trodelvy fails in lung cancer and raises new questions on antibody drug conjugate drugs  STAT
  3. Gilead Sinks After Lung Cancer Drug Fails to Improve Survival  Bloomberg

Want the full story? Read the original reporting

Read on MarketWatch